August 2026– date –
-
EMA CHMP Recommends 12 Medicines for Approval, Including 3 New Hypercholesterolemia Drugs and Therapies for Cholestatic Pruritus and Cerebral Adrenoleukodystrophy
EMA EU Overview The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for twelve medicines at its July 2026 meeting. This includes three new medicines for hypercholesterolemia or mixed dyslipidemia: Ly... -
Eli Lilly’s Retatrutide Emerges as Most Powerful Obesity Drug Yet, Achieves Five Consecutive Positive Phase 3 Readouts in TRIUMPH Program
Drug Discovery News USA Overview Eli Lilly's triple agonist retatrutide has shown positive results in metabolic disease, positioning it as a powerful obesity drug. The company has achieved five consecutive positive Phase 3 readouts acros... -
LNP-Mediated Gene Therapy to Correct ACTA2 Mutations Shows Promise: Reduces Stroke-Related Mortality, Offers Re-dosability & Lower Costs Over Viral Vectors
MSMDS.org USA Overview A novel lipid nanoparticle (LNP)-based gene therapy strategy is under development to correct ACTA2 mutations in vascular smooth muscle cells. This approach offers significant advantages over viral vectors, includin... -
Daiichi Sankyo’s Early ADC Pipeline Lags Rivals as Cash Flow Nears Peak, Incurs $850M Charges for Underutilized CMO Capacity
BioSpace USA Overview Jefferies analysts suggest Daiichi Sankyo's early-stage antibody-drug conjugate (ADC) pipeline is not keeping pace with rivals, despite the success of Enhertu and Datroway. Enhertu and Datroway are nearing peak reve... -
Complete Guide to Lipid Nanoparticles (LNP): Foundational Technology for Nucleic Acid Delivery Validated by mRNA Vaccine Success
Inside Therapeutics USA Overview Lipid nanoparticles (LNPs) are nanoscale delivery vehicles designed to protect and deliver nucleic acids like mRNA and siRNA into cells, serving as the delivery platform for COVID-19 mRNA vaccines. LNPs o... -
Biopharmaceuticals Contract Manufacturing Market Expands Amid Global Demand: CDMOs Scale Up Capacity
openPR.com Unknown Overview This article provides an overview of a market research report published by openPR.com. The biopharmaceutical contract manufacturing market is growing due to increased demand for biosimilars, expanded investmen... -
Advances in LNP-Mediated Nucleic Acid Delivery to Respiratory & GI Mucosa: AI Integration for Personalized DDS Future
MDPI Switzerland Overview Lipid nanoparticles (LNPs) are rapidly advancing as a versatile platform to overcome delivery barriers for nucleic acids to respiratory and gastrointestinal mucosal sites. LNPs offer tunable physicochemical prop... -
First PROTAC Approval Validates Targeted Protein Degradation as a Breakthrough Modality for Cancer Treatment
Converge Bio Unknown Overview The FDA approval of vepdegestrant, developed by Arvinas and Pfizer, signifies a major milestone for targeted protein degradation (TPD). This first-in-class PROTAC, approved for ER+/HER2-, ESR1-mutated advanc... -
FDA Approves First PROTAC Vepdegestrant (ARV-471) for ER+/HER2- Breast Cancer, Ushering in a New Era of Targeted Protein Degradation
Journal of Medicinal Chemistry - ACS Publications USA Overview On May 1, 2026, the FDA approved vepdegestrant (ARV-471; Veppanu), making it the first heterobifunctional PROTAC protein degrader approved for clinical practice. Indicated fo... -
Eli Lilly’s Triple Agonist Retatrutide Achieves 21-23% Weight Loss in Diabetic and CVD Patients Over 80 Weeks, Nears FDA Submission
BioPharma Dive USA Overview Eli Lilly is preparing to seek FDA approval for its obesity drug retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors. New data from the Triumph-2 and Triumph-3 studies showed average bod...
